Gilead spending $50 million to test and manufacture COVID-19 drug candidate remdesivir
April 30, 2020 at 16:23 PM EDT
Gilead Sciences Inc. reported better-than-expected earnings for the first quarter of the year Thursday, and detailed more of its work on remdesivir, an antiviral drug candidate aimed at helping COVID-19 patients.
